Related Experiment Video
Updated: Jun 25, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Targeting malignant glioma cells in vitro using platelet-derived growth factor AA-based conjugates
Maria Dahlström Wester1, Ake Wasteson, Annelie Lindström
1Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden. maria.wester@liu.se
Abstract:
Glioblastoma multiforme (GBM) is an unusually aggressive brain tumor; it is also highly heterogeneous. Poor prognosis and a median survival of less than 1 year, using conventional treatment, calls for development of new treatment strategies. Overexpression and/or amplification of platelet-derived growth factor alpha receptors (PDGF alpha Rs) in GBM might act as potential targets for a novel therapeutic approach. In this study, conjugates based on PDGFAA-ligand and dextran, of different sizes (10 and 40 kDa dextran), were prepared and investigated regarding targeting properties in vitro. Three human malignant glioma cell lines, U343MGa31L, U343MGaCl2:6, and U563MG, were used because of their previously reported differences in receptor expression and behavior. PDGFAA-based 10 kDa dextran iodine-125 radiolabeled conjugates showed the most favorable properties according to results achieved in accumulation, retention, and localization of cell-associated radioactivity. In comparison with dextran-(125)I-tyrosine delivered radioactivity, the PDGFAA-based dextran conjugates confirm the potential of receptor targeting.
Insights
New treatments for glioblastoma multiforme (GBM) are needed. Researchers developed platelet-derived growth factor alpha receptor (PDGF alpha R)-targeted conjugates, with 10 kDa dextran conjugates showing the most promise for GBM therapy.
Area of Science:
- Oncology
- Biochemistry
- Radiochemistry
Background:
- Glioblastoma multiforme (GBM) is a highly aggressive and heterogeneous brain tumor with poor patient prognosis.
- Conventional treatments offer limited efficacy, necessitating novel therapeutic strategies.
- Platelet-derived growth factor alpha receptors (PDGF alpha Rs) are overexpressed in GBM, presenting a potential therapeutic target.
Purpose of the Study:
- To investigate the potential of platelet-derived growth factor alpha ligand (PDGFAA)-conjugated dextran as a targeted therapeutic agent for glioblastoma.
- To evaluate the in vitro targeting properties of PDGFAA-dextran conjugates of varying sizes.
Main Methods:
- Preparation of PDGFAA-ligand and dextran conjugates (10 kDa and 40 kDa dextran).
- Radiolabeling of conjugates with iodine-125 (¹²⁵I).
- In vitro evaluation of conjugate accumulation, retention, and cell-associated radioactivity in three human malignant glioma cell lines (U343MGa31L, U343MGaCl2:6, U563MG) with differing receptor expression.
Main Results:
- PDGFAA-based 10 kDa dextran ¹²⁵I-labeled conjugates demonstrated superior accumulation, retention, and localization of cell-associated radioactivity compared to controls.
- The PDGFAA-based dextran conjugates showed enhanced targeting properties.
- Results were compared against dextran-¹²⁵I-tyrosine delivered radioactivity.
Conclusions:
- PDGFAA-dextran conjugates exhibit promising receptor-targeting capabilities for glioblastoma.
- The 10 kDa dextran conjugate size appears optimal for enhanced targeting of PDGF alpha R-expressing glioma cells.
- These findings support the potential of PDGF alpha R-targeted conjugates as a novel therapeutic approach for glioblastoma.
